Corpus overview


Overview

MeSH Disease

Transmission

Seroprevalence
    displaying 31 - 40 records in total 507
    records per page




    Analysis of the Effect of Proton Pump Inhibitors on the Course of Common COVID-19 MESHD

    Authors: xiaoyu ZHANG; Haibing Wu; Yun Ling; Liang Chen

    doi:10.21203/rs.3.rs-90738/v1 Date: 2020-10-10 Source: ResearchSquare

    Background/aims: This study is to evaluate the effect of proton pump inhibitors on the course of common COVID-19 MESHD.Methods: Clinical data of common COVID-19 MESHD patients admitted to the Shanghai Public Health Clinical Center for treatment from January 20, 2020 to March 16, 2020 were collected. A retrospective study was conducted and the patients were divided into two groups according to whether they used proton pump inhibitors or not. The differences in SARS-CoV-2 clearance and hospital stay between the two groups were compared by univariate and multivariate analyses.Results: A total of 154 COVID-19 MESHD common cases were included in this study, including 80 males TRANS (51.9%), 35 patients (22.7%) in the proton pump inhibitors group, and 119 patients (77.3%) in the control group. In the proton pump inhibitors group and the control group, the duration of the SARS-CoV-2 clearance were 7(6-9) and 7(6-11) days, and the duration of the hospital stay was 21(16-25) and 20(15-26) days, respectively. There was no significant difference between the two groups in the cumulative incidence of the SARS-CoV-2 clearance and the discharge, all P > 0.05. Multivariate analysis showed that chronic gastropathy prolonged MESHD the duration of SARS-CoV-2 clearance, the HR was 20.924(3.547-123.447). Hypertension HP Hypertension MESHD, chronic obstructive pulmonary disease HP obstructive pulmonary disease MESHD, chronic liver disease MESHD and malignant tumor MESHD all increased the duration of hospital stay for COVID-19 MESHD, and the HR were 1.820 (1.073-3.085), 4.370 (1.205-15.844), 9.011 (2.681-30.290) and 5.270 (1.237-22.456), respectively; the duration of the hospital stay in COVID-19 MESHD patients was shortened by the SARS-CoV-2 clearance, and the HR was 0.907 (0.869-0.947); all P < 0.05.Conclusion:  Proton pump inhibitors use has no effect on the prolonging or shortening of the course of adults TRANS hospitalized with COVID-19 MESHD.

    Incidence and Risk Factors of Illnesses Presumably Caused by A SARS-CoV-2 Infection MESHD in The General Population During The Lockdown Period: A Multi-Cohort Study.

    Authors: Fabrice Carrat; Mathilde Touvier; Gianluca Severi; Laurence Meyer; Florence Jusot; Nathanael Lapidus; Delphine Rahib; Nathalie Lydié; Marie-Aline Charles; Pierre-Yves Ancel; Alexandra Rouquette; Xavier de Lamballerie; Marie Zins; Nathalie Bajos

    doi:10.21203/rs.3.rs-90873/v1 Date: 2020-10-10 Source: ResearchSquare

    Background Our main objectives were to estimate the incidence of illnesses presumably caused by SARS-CoV-2 infection MESHD during the lockdown period and to identify the associated risk factors.Methods Participants from 3 adult TRANS cohorts in the general population in France were invited to participate in a survey on COVID-19 MESHD. The main outcome was possible COVID-19 MESHD, defined as a sudden onset of cough HP, fever HP fever MESHD, dyspnea HP dyspnea MESHD, ageusia and/or anosmia MESHD anosmia HP, that lasted more than 3 days and occurred during the 17 days before the survey. We used delayed-entry Cox models to identify associated factors.Results Between April 2, 2020 and May 12, 2020, 279,478 participants were invited, 116,903 validated the questionnaire and 106,848 were included in the analysis. Three thousand thirty-five cases of possible COVID-19 MESHD were reported during 62,099 person-months of follow-up. The cumulative incidences of possible COVID-19 MESHD were 6.2% (95% Confidence Interval (95%CI): 5.7%; 6.6%) on day 15 and 8.8% (95%CI 8.3%; 9.2%) on day 45 of lockdown. The risk of possible COVID-19 MESHD was lower in older age groups TRANS and higher in French regions with a high prevalence SERO of SARS-CoV-2 infection MESHD, in participants living in cities >100,000 inhabitants (vs rural areas), when at least one child TRANS or adolescent was living in the same household, in overweight HP or obese people MESHD, and in people with chronic respiratory diseases MESHD, anxiety HP anxiety MESHD or depression or chronic diseases MESHD other than diabetes MESHD, cancer MESHD, hypertension MESHD hypertension HP or cardiovascular diseases MESHD. Conclusion The incidence of possible COVID-19 MESHD in the general population remained high during the first two weeks of lockdown, and decreased significantly thereafter. Modifiable and non-modifiable risk factors were identified.

    Clinical characteristics, management and health-related quality of life in young adults TRANS with COVID-19 MESHD 

    Authors: Chiara Temperoni; Francesco Barchiesi

    doi:10.21203/rs.3.rs-90294/v1 Date: 2020-10-09 Source: ResearchSquare

    Background The outbreak of COVID-19 MESHD has rapidly spread to Italy, including Pesaro-Urbino province. Data on young adults TRANS with COVID-19 MESHD are lacking. We report the characteristics, management and health-related quality of life (HRQoL) in patients with COVID-19 MESHD aging ≤50 years.Methods A retrospective analysis was performed in all patients ≤50 years with a confirmed diagnosis of COVID-19 MESHD admitted to Emergency department (ED) of San Salvatore Hospital in Pesaro from February 28th to April 8th, 2020. Data were collected from electronical medical records. HRQoL was investigated after one month from hospital discharge. Outcomes were evaluated between hospitalized and not hospitalized patients.Results: Among 673 patients admitted to the ED and diagnosed with COVID-19 MESHD, 104 (15%) were ≤50 years old: 74% were discharged at home within 48 h, 26% were hospitalized. Fever HP ever MESHDoccurred in 90% of the cases followed by cough HP (56%) and d yspnoea MESHD(34%). Chest X-ray and/or CT scan revealed ground glass opacity, bilateral patch shadow or focal lesions in 27%, 37% and 10% of the patients, respectively. The most frequent coexisting conditions were hypertension HP ypertension MESHD(11%), t hyroid dysfunction MESHD(8%) and neurological and/or m ental disorders MESHD[N MDs] MESHD (6%). Mean BMI was 27. H ypokalaemia and NMDs MESHDwere significantly more common in patients who underwent mechanical ventilation. Regardless of hospitalization, there was a significant impairment in both the physical and mental functioning.Conclusions Overweight HP and hypertension HP ypertension MESHDare frequent conditions in young adults TRANS with COVID-19 MESHD. H ypokalaemia and NMDs MESHDare commonly associated with progressive disease. There is a significant impact on HRQoL in the early stage of post-discharge.

    EFFECT OF CONVALESCENT PLASMA SERO ON MORTALITY IN PATIENTS WITH COVID-19 MESHD PNEUMONIA HP

    Authors: Martin R Salazar; Soledad E Gonzalez; Lorena Regairaz; Noelia S Ferrando; Veronica Gonzalez; Patricia M Carrera; Laura Muñoz; Santiago A Pesci; Juan M Vidal; Nicolas Kreplak; Elisa Estenssoro; Harendra Guturu; Ahna R. Girshick; Kristin A. Rand; Eurie L. Hong; Catherine A. Ball; Stefan VANEL; Pierre MENDIHARAT; Klaudia PORTEN; William HENNEQUIN; Clair MILLS; Francisco LUQUERO

    doi:10.1101/2020.10.08.20202606 Date: 2020-10-09 Source: medRxiv

    Abstract Background Convalescent plasma SERO, widely utilized in viral infections that induce neutralizing antibodies SERO, has been proposed for COVID-19 MESHD, and preliminary evidence shows that it might have beneficial effect. Our objective was to compare epidemiological characteristics and outcomes between patients who received convalescent plasma SERO for COVID-19 MESHD and those who did not, admitted to hospitals in Buenos Aires Province, Argentina, throughout the pandemic. Methods This is a multicenter, retrospective cohort study of 2-month duration beginning on June 1, 2020, including unselected, consecutive adult TRANS patients with diagnosed COVID-19 MESHD, admitted to 215 hospitals with pneumonia HP pneumonia MESHD. Epidemiological and clinical variables were registered in the Provincial Hospital Bed Management System. Convalescent plasma SERO was supplied as part of a centralized, expanded access program. Results We analyzed 3,529 patients with pneumonia MESHD pneumonia HP, predominantly male TRANS, aged TRANS 62{+/-}17, with arterial hypertension HP hypertension MESHD and diabetes MESHD as main comorbidities; 51.4% were admitted to the ward, 27.1% to the Intensive Care Unit (ICU), and 21.7% to the ICU with mechanical ventilation requirement (ICU-MV). 28-day mortality was 34.9%; and was 26.3%, 30.1% and 61.4% for ward, ICU and ICU-MV MESHD patients. Convalescent plasma SERO was administered to 868 patients (24.6%); their 28-day mortality was significantly lower (25.5% vs. 38.0%, p<0.001). No major adverse effects occurred. Logistic regression analysis identified age TRANS, ICU admission with and without MV requirement, diabetes MESHD and preexistent cardiovascular disease MESHD as independent predictors of 28-day mortality, whereas convalescent plasma SERO administration acted as a protective factor. Conclusions Our study suggests that the administration of convalescent plasma SERO in COVID-19 MESHD pneumonia HP pneumonia MESHD admitted to the hospital might be associated with decreased mortality.

    Clinical Course and Features of Critical Patients with COVID-19 MESHD: A Single- Center, Retrospective Study from Wuhan Huoshenshan Hospital

    Authors: Huisi He; Zhichao Jin; Yibin Ren; Junxue Wang; Shuzhen Chen; Wen Wen; Yushan Miao; Xuewei Qi; Taiyu Shang; Chenxu Zhang; Hongyang Wang; Weiqin Li; Xijing Zhang; Hao Tang

    doi:10.21203/rs.3.rs-89722/v1 Date: 2020-10-08 Source: ResearchSquare

    Background: Nationally, the indicators tracking the coronavirus pandemic has remained stable. However, it’s still a public health concern and it’s worth providing more front-line data on critical illness. We aim to investigate the clinical course and features of critical patients with Corona Virus Disease MESHD 2019 ( COVID-19 MESHD).Methods: The data on 124 consecutive critical patients from 8th February through April 16th 2020, including demographic and clinical information, were obtained from the intensive care unit (ICU) of Wuhan Huoshenshan Hospital. A cross-sectional survey and comparisons of key biomarkers between survivors and nonsurvivors were performed.Results: Over the study period, 57 nonsurvivors and 67 survivors were included. The overall case-fatality rate for critical patients with COVID-19 MESHD was approximately 46%. The overall average age TRANS was 69.89±11.03 years, and the majority had underlying health problems such as hypertension HP hypertension MESHD (63[51%]) and diabetes MESHD (27[22%]). Compared with survivors, nonsurvivors were more likely to develop sepsis MESHD sepsis HP (57[100%] vs. 34[51%]), acute respiratory distress syndrome MESHD respiratory distress HP syndrome (52[91%] vs. 21[38%]) and organ dysfunction. Besides, the dynamic changes in some biomarkers (i.e. WBC, TLC, CRP, PLT) were significantly different between the two groups. The trajectories of temperature revealed that the group with a high temperature on admission that steadily declined had the highest percentage of deaths (84.21%).Conclusions: The elderly TRANS with many concomitant diseases were at the highest risk. Lymphocyte, platelet, C-reactive protein and temperature were revealed to have potential as prognostic factors, whereas some other biomarkers, such as hepatic enzymes, may not offer additional information. Moreover, patients with high temperatures on admission should receive extra care.

    Comparing biomarkers for COVID-19 MESHD disease with commonly associated preexisting conditions and complications.

    Authors: Jesse Huang; Aditya M Rao; Denis Dermadi; Jiaying Toh; Lara Murphy Jones; Michele Donato; Yiran Liu; Yapeng Su; Minas Karagiannis; Theodoros Marantos; Yehudit Hasin-Brumshtein; Yudong D He; Evangelos J Giamarellos-Bourboulis; Jim Heath; Purvesh Khatri

    doi:10.1101/2020.10.02.20205609 Date: 2020-10-05 Source: medRxiv

    Severe coronavirus disease 2019 MESHD ( COVID-19 MESHD) has been associated with certain preexisting health conditions and can cause respiratory failure MESHD respiratory failure HP along with other multi-organ injuries. However, the mechanism of these relationships is unclear, and prognostic biomarkers for the disease and its systemic complications are lacking. This study aims to examine the plasma SERO protein profile of COVID-19 MESHD patients and evaluate overlapping protein modules with biomarkers of common comorbidities. Blood SERO samples were collected from COVID-19 MESHD cases (n=307) and negative controls (n=78) among patients with acute respiratory distress MESHD respiratory distress HP. Proteins were measured by proximity extension assay utilizing next-generation sequencing technology. Its associations to COVID-19 MESHD disease characteristics were compared to that of preexisting conditions and established biomarkers for myocardial infarction MESHD myocardial infarction HP ( MI MESHD), stroke MESHD stroke HP, hypertension HP hypertension MESHD, diabetes MESHD, smoking, and chronic kidney disease HP chronic kidney disease MESHD. Several proteins were differentially expressed in COVID-19 MESHD, including multiple pro-inflammatory cytokines such as IFN-gamma, CXCL10, and CCL7/MCP-3. Elevated IL-6 was associated with increased severity, while baseline IL1RL1/ST2 levels were associated with a worse prognosis. Network analysis identified several protein modules associated with COVID-19 MESHD disease characteristics overlapping with processes of preexisting hypertension HP hypertension MESHD and impaired kidney function MESHD. BNP and NTpro-BNP, markers for MI MESHD and stroke MESHD stroke HP, increased with disease progression and were positively associated with severity. MMP12 was similarly elevated and has been previously linked to smoking and inflammation in emphysema MESHD emphysema HP, along with increased cardiovascular disease MESHD risk. In conclusion, this study provides an overview of the systemic effects of COVID-19 MESHD and candidate biomarkers for clinical assessment of disease progression and the risk of systemic complications.

    Metabolic syndrome MESHD increases COVID-19 MESHD-related mortality in the UK Biobank sample

    Authors: Filip Morys; Alain Dagher; Ivor S Douglas; Efren Murillo-Zamora; Lara Murphy Jones; Michele Donato; Yiran Liu; Yapeng Su; Minas Karagiannis; Theodoros Marantos; Yehudit Hasin-Brumshtein; Yudong D He; Evangelos J Giamarellos-Bourboulis; Jim Heath; Purvesh Khatri

    doi:10.1101/2020.10.02.20205716 Date: 2020-10-05 Source: medRxiv

    Previous studies link obesity HP obesity MESHD and individual components of metabolic syndrome MESHD to increased hospitalisations and death rates of patients with COVID-19 MESHD. Here, in two overlapping samples of over 1,000 individuals from the UK Biobank we investigate whether metabolic syndrome MESHD, and its constituent components, increased waist circumference, dyslipidaemia, hypertension MESHD hypertension HP, diabetes MESHD, and systemic inflammation MESHD, are related to increased COVID-19 MESHD infection and mortality rates. Using logistic regression and controlling for confounding variables such as socioeconomic status, age TRANS, sex or ethnicity, we find that individuals with pre-existing metabolic syndrome MESHD (measured on average eleven years prior to 2020) have an increased risk for COVID-19 MESHD-related death (odds ratio 1.67). We also find that specific factors contributing to increased mortality are serum SERO glucose levels, systolic blood SERO pressure and waist circumference.

    A national study of self-reported COVID symptoms during the first viral wave in Canada

    Authors: Xuyang Tang; Hellen Gelband; Teresa Lam; Nico Nagelkerke; Angus Reid; Prabhat Jha; - Action to beat Coronavirus (Ab-C) Study Investigators; Jakob Trimpert; Jens Bukh; Klaus Osterrieder; Judith Gottwein; Peter H Seeberger; Evangelos J Giamarellos-Bourboulis; Jim Heath; Purvesh Khatri

    doi:10.1101/2020.10.02.20205930 Date: 2020-10-05 Source: medRxiv

    Importance: Accurate understanding of COVID pandemic during the first viral wave in Canada could help prepare for future epidemic waves. Objective: To track the early course of the pandemic by examining self-reported COVID symptoms over time before testing became widely available. Design: Adults TRANS from the nationally representative Angus Reid Forum were randomly invited to complete an online survey in May/June 2020. The study is a part of the Action to Beat Coronavirus antibody testing SERO study. Setting: A 20-item internet survey. Participants: 14,408 adults TRANS age TRANS 18 years of age TRANS. Exposures: The months that respondents and any household members first experienced various respiratory, neurological, sleep, skin or gastric symptoms MESHD. Main Outcomes and Measure: COVID symptom-positive, defined as fever MESHD fever HP (or fever HP fever MESHD with hallucinations MESHD hallucinations HP) plus at least one of difficulty breathing, a dry severe cough HP, loss of smell or COVID toe. Results: In total, 14,408 panel members (48% male TRANS and 52% female TRANS) completed the survey. Despite overrepresentation of higher levels of education, the prevalence SERO of obesity MESHD obesity HP, smoking, diabetes MESHD and hypertension HP hypertension MESHD were similar to national census and health surveys. A total of 811 (5.6%) were COVID symptom-positive; highest rates were at ages TRANS 18-44 years (8.3% among), declining at older ages TRANS. Females TRANS had higher odds of reporting COVID symptoms (OR = 1.32, 95%CI 1.11-1.56) as did visible minorities (OR = 1.74, 1.29-2.35). COVID symptom positivity for respondents and their household members peaked in March (OR = 1.93, 95% CI = 1.59-2.34 compared to earlier months). Conclusions and Relevance: This study enhances our current understanding of the progression of the COVID epidemic in Canada, with few laboratory- confirmed cases TRANS in January and February, peaking in April. The results suggest substantial viral transmission TRANS in March, before widespread testing began, and a gradual decline in cases since May.

    Genetic and non-genetic factors affecting the expression of COVID-19 MESHD relevant genes in the large airway epithelium

    Authors: Silva Kasela; Victor E Ortega; Molly Martorella; Suresh Garudadri; Jenna Nguyen; Elizabeth Ampleford; Anu Pasanen; Srilaxmi Nerella; Kristina L Buschur; Igor Z Barjaktarevic; R Graham Barr; Eugene R Bleecker; Russell P Bowler; Alejandro P Comellas; Christopher B Cooper; David J Couper; Gerard J Criner; Jeffrey L Curtis; MeiLan K Han; Nadia N Hansel; Eric A Hoffman; Robert J Kaner; Jerry A Krishnan; Fernando J Martinez; Merry-Lynn N McDonald; Deborah A Meyers; Robert Paine III; Stephen P Peters; Mario Castro; Loren C Denlinger; Serpil C Erzurum; John V Fahy; Elliot Israel; Nizar N Jarjour; Bruce D Levy; Xingnan Li; Wendy C Moore; Sally E Wenzel; Joe Zein; - NHLBI SubPopulations and InteRmediate Outcome Measures In COPD Study (SPIROMICS); - NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium; Charles Langelier; Prescott G Woodruff; Tuuli Lappalainen; Stephanie A Christenson

    doi:10.1101/2020.10.01.20202820 Date: 2020-10-04 Source: medRxiv

    Particular host and environmental factors influence susceptibility to severe COVID-19 MESHD. We analyzed RNA-sequencing data from bronchial epithelial brushings - a relevant tissue for SARS-CoV-2 infection MESHD - obtained from three cohorts of uninfected individuals, and investigated how non-genetic and genetic factors affect the regulation of host genes implicated in COVID-19 MESHD. We found that ACE2 expression was higher in relation to active smoking, obesity HP obesity MESHD, and hypertension MESHD hypertension HP that are known risk factors of COVID-19 MESHD severity, while an association with interferon-related inflammation MESHD was driven by the truncated, non-binding ACE2 isoform. We discovered that expression patterns of a suppressed airway immune response to early SARS-CoV-2 infection MESHD, compared to other viruses, are similar to patterns associated with obesity MESHD obesity HP, hypertension HP hypertension MESHD, and cardiovascular disease MESHD, which may thus contribute to a COVID-19 MESHD-susceptible airway environment. eQTL mapping identified regulatory variants for genes implicated in COVID-19 MESHD, some of which had pheWAS evidence for their potential role in respiratory infections MESHD. These data provide evidence that clinically relevant variation in the expression of COVID-19 MESHD-related genes is associated with host factors, environmental exposures, and likely host genetic variation.

    Universal health care access for all residents reduce mortality in COVID-19 MESHD patients in Abu Dhabi, UAE: A retrospective multicenter cohort study

    Authors: Nawal Al kaabi; Asma Al Nuaimi; Mariam Al Harbi; Jehad Abdalla; Tehmina Khan; Huda Gasmelseed; Asad Khan; Osama Hamdoun; Stefan Weber

    doi:10.21203/rs.3.rs-87753/v1 Date: 2020-10-04 Source: ResearchSquare

    Background: SARS‐CoV‐2 was first reported in December 2019. The severity of COVID-19 MESHD infection ranges from being asymptomatic to severe infection HP leading to death. The aim of the study is to describe the clinical characteristics and outcomes of hospitalized COVID-19 MESHD patients within the largest government healthcare facilities in the Emirate of Abu Dhabi, the capital of UAE. Methods:  This paper is a retrospective cross-sectional study of all patients admitted to Abu Dhabi Healthcare services facilities (SEHA) between the period of March 1st until May 31st with a laboratory-confirmed test of SARS-CoV2, known as Coronavirus disease MESHD ( COVID19 MESHD). Variation in characteristics, comorbidities, laboratory values, length of hospital stay, treatment received and outcomes were examined. Data was collected from electronic health records available at SEHA health information system.Results: There were 9390 patients included; patients were divided into severe and non-severe groups. 721 (7.68%) patients required intensive care while the remaining majority (92.32 %) were mild-moderate cases. The mean age TRANS (41.8 years) is less than the mean age TRANS reported globally. Our population had a male TRANS predominance and variable representation of different nationalities. Three major comorbidities were noted, hypertension MESHD hypertension HP, diabetes mellitus MESHD diabetes mellitus HP and chronic kidney disease HP chronic kidney disease MESHD. The laboratory tests that were significantly different between the severe and the non-severe groups were LDH, Ferritin, CRP, neutrophil count, IL6 and creatinine level. The major antiviral therapies the patients have received were a combination of hydroxychloroquine and favipiravir. The overall in hospital mortality was 1.63% while severe group mortality rate was 19.56 %. The Death rate in the adults TRANS younger than 30 years was noted to be higher compared to elderly TRANS patients above 60 years, 2.3% and 0.9 % respectively. Conclusion: our analysis suggests that Abu Dhabi had a relatively low morbidity and mortality rate and a high recovery rate compared to published rates in China, Italy and The United States. The demographic of the population is younger and has an international representation. The country had the highest testing rate in relation to the population volume. We believe the early identification and younger demographic had affected the favorable comparative outcome in general with early identification of cases leading to a lower mortality rate. 

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.